Open AccessOmalizumab and adalimumab: a winning couple
Author(s) -
Laura Diluvio,
Laura Vollono,
Arianna Zangrilli,
Valeria Manfreda,
Monia Di Prete,
Antonio Massaro,
Stella Modica,
Elisabetta Greco,
Luca Bianchi,
Elena Campione
Publication year - 2020
Publication title -
immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.127
H-Index - 48
eISSN - 1750-7448
pISSN - 1750-743X
DOI - 10.2217/imt-2020-0203
Subject(s) - omalizumab , adalimumab , medicine , dermatology life quality index , psoriatic arthritis , concomitant , dermatology , quality of life (healthcare) , psoriasis , immunoglobulin e , immunology , antibody , rheumatoid arthritis , nursing
We report a case of a young female patient, previously affected by psoriatic arthritis, and treated with adalimumab, who developed a chronic spontaneous urticaria and started a concomitant therapy with omalizumab. Methods & results: A 50% reduction of the Dermatology Life Quality Index (from 7 at baseline to 4 in weeks 12 and 24) and a complete reset of the Urticaria Activity Score for 7 days (from 27 at baseline to 0 in weeks 12 and 24) were recorded. During all treatment with omalizumab, administering of adalimumab was continued. Due to complete control of urticaria symptoms, the patient stopped treatment with omalizumab after 24 weeks. Conclusion: The combination of adalimumab and omalizumab could offer a favorable efficacy and safety profile. The synergistic action of the two biological drugs in reducing systemic inflammation could be responsible for a shorter time to obtain clinical response.